About RS Research
This author has not written his bio yet.
But we are proud to say that RS Research contributed 66 entries already.
Entries by RS Research
RS Research RS-0139’un Faz 1 Klinik Araştırmasında Doz Artırıldığını Duyurdu
Hedefli kemoterapiyi mümkün kılacak akıllı ilaç adayları geliştiren Türk biyoteknoloji girişimi RS Research, RS-0139’un akciğer kanseri endikasyonunda yürütülen Faz 1 klinik araştırmasında (RS-001) bir sonraki aşamaya geçildiğini duyurdu. […]
RS Research announces dose escalation in the phase 1 clinical study of RS-0139
Designing drug candidates with a superior therapeutic index, RS Research will advance to the next dose cohort following the positive review of the safety data from the dosing of the first cohort by the Independent Data Monitoring Committee (IDMC). Medical experts of IDMC recommended […]
BIOWORLD
PDC Therapeutics building better docetaxel therapy with nanocarrier technology
GAZETE OKSIJEN
From Bench to Bedside: first ever in Turkey
HABERTURK
International Women’s Day Interview with Prof. Rana Sanyal
FIERCE PHARMA
Turkish biotech bags $12M for targeted delivery of cancer drugs
RS Research announces first patient dosed in phase 1 clinical trial of RS-0139 in NSCLC
RS Research announced that the first patient has been dosed in the Phase I clinical trial evaluating the safety of RS-0139 in NSCLC. RS Research’s pipeline is based on the proprietary platform technology Sagitta©, which are nanocarriers with versatile targeting capability and suitable […]
RS Research’ün geliştirdiği ilaç adayı RS-0139 klinik araştırmada ilk hastaya uygulandı
Hedefli kemoterapiyi mümkün kılacak akıllı ilaç adayları geliştiren biyoteknoloji girişimi RS Research, portföyünün en önde giden ilaç adayı RS-0139’un akciğer kanseri endikasyonunda yürütülen Faz 1 klinik araştırmasında ilk hastaya uygulandığını duyurdu. […]
SABAH
Biotech startup raises $12M in Series A Investment Round
RS Research is a clinically-validated biotech company developing targeted oncology therapies using Sagitta® drug-delivery platforms, disrupting the efficacy-toxicity trade-off.
